| Bioactivity | DCPT1061 potently inhibits PRMT1, PRMT6 and PRMT8 in vitro with less inhibitory effect on PRMT3, PRMT4, and PRMT5 or other epigenetic enzymes. DCPT1061 has antitumor effect[1][2]. |
| Name | DCPT1061 |
| CAS | 2289726-31-2 |
| Formula | C17H20Cl2N2O |
| Molar Mass | 339.26 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Jianfeng Wang, et al. PRMT1 is a novel molecular therapeutic target for clear cell renal cell carcinoma. Theranostics. 2021 Mar 12;11(11):5387-5403. [2]. Hongru Tao, et al. PRMT1 inhibition activates the interferon pathway to potentiate antitumor immunity and enhance checkpoint blockade efficacy in melanoma. Cancer Res. 2023 Nov 22. |
DCPT1061
CAS: 2289726-31-2 F: C17H20Cl2N2O W: 339.26
DCPT1061 potently inhibits PRMT1, PRMT6 and PRMT8 in vitro with less inhibitory effect on PRMT3, PRMT4, and PRMT5 or oth
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.